Figure 5.

Laboratory abnormalities and changes in blood lipids associated with oral rilpivirine as a component of combination therapy in antiretroviral-naïve patients with HIV infection.

Notes: Pooled descriptive data¹⁰ from the ECHO²⁴ and THRIVE trials²⁵ are for severity-level grades 2–4 laboratory abnormalities or changes in blood lipids occurring in ≥2% of patients in at least one group after 48 weeks of treatment. Values shown as <1 at a particular grade level of severity in the original reference were rounded up to 1 when summing to obtain totals for grade 2–4 levels.

Abbreviations: BR, background regimen; EFV, efavirenz; LDL, low-density lipoprotein; RPV, rilpivirine; AST, aspartate aminotransferase; ALT, alanine aminotransferase.